The review has drawn attention from IP counsel, including commentary from Foley & Lardner attorney Oyvind Dahle on implications for patent strategy in AI-driven drug discovery. The broader landscape includes AI-native firms like Deargen and Innoverry, academic programs at institutions like Chongqing University, and regulatory support through the USPTO's extension of its AI Search Automated Pilot program through June 1, 2026, which streamlines prior art searches in patent applications. The FDA fast-tracked 12 AI-identified oncology drugs in 2024, signaling institutional acceptance of the technology.
AI compresses preclinical timelines from years to months and reduces costs by approximately 40 percent, but creates novel IP risks. Premature patents on unvalidated candidates and inventorship gaps under EPC Article 81 and U.S. law remain unresolved. With over 60 AI drug discovery patents expected to surge through 2026 and acute pressure to replenish pipelines amid patent cliffs costing $180 billion in U.S. revenue through 2030, patent counsel should prioritize rigorous analysis of AI-generated candidates to distinguish viable inventions from scaled outputs.